|
 The company in June recalled up to four million of its respiratory
devices and ventilators, as it said a foam part might degrade and
become toxic, potentially causing cancer.
Philips said it had received authorisation from the U.S. Food and
Drug Administration (FDA) for the rework of the affected
DreamStation device, allowing it to replace the sound abatement foam
with a new material.
More than half of the affected machines have been sold in the U.S.
and the full replacement effort will take about a year, Philips
said.
[to top of second column] |
 Philips shares have lost about
15% of their value since the recall, as
investors fear the possible costs of a number of
class action lawsuits that have been launched
over the affair.
Philips has set aside 500 million euros ($590
million) in provisions for the recall operation
in the first half of 2021.
($1 = 0.8478 euros)
(Reporting by Bart Meijer, Editing by Louise
Heavens)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
